FUJIFILM Diosynth Biotechnologies (Fujifilm), a CDMO with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies, has introduced its next generation Apollo mammalian expression system, Apollo X. The Apollo X advanced mammalian expression system is capable of delivering industry leading titres in excess of 10 g/L and is designed to be a ‘manufacturing-ready’ cell line with a robust support package to aid IND filing.
We have focused on optimizing the cell line development process without compromising quality. And we have achieved that while reaching titres of 10g/L and higher in fed-batch processes.
said Andy Topping, chief scientific officer at FUJIFILM Diosynth Biotechnologies.
Apollo X consists of four key components: a CHO-DG44-derived host cell line selected through a directed evolution approach to control and manage cellular heterogeneity. The selected cell line has been fully sequenced and analyzed; a novel expression vector with a proprietary leader sequence developed for efficient secretion and high productivities without the need for amplification; a proprietary cell culture medium specifically screened for achieving high titres by monitoring initial cell growth, controlling peak cell density and maintaining high cell viability; streamlined units of operations for efficient process implementation.
According to the company, Apollo X cell line development timelines have been reduced by 30%, from gene to clonal cell line compared to the original Apollo expression system.